BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12414850)

  • 21. Bone turnover markers and bone density across the menopausal transition.
    Ebeling PR; Atley LM; Guthrie JR; Burger HG; Dennerstein L; Hopper JL; Wark JD
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3366-71. PubMed ID: 8784098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen.
    Rapuri PB; Gallagher JC; Knezetic JA; Haynatzka V
    Maturitas; 2006 Mar; 53(4):371-9. PubMed ID: 16139450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical parameters associated with low bone density in healthy men and women.
    Sherman SS; Tobin JD; Hollis BW; Gundberg CM; Roy TA; Plato CC
    J Bone Miner Res; 1992 Oct; 7(10):1123-30. PubMed ID: 1456082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
    Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
    Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I; Vignau J; Collier F; Cortet B
    Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
    Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
    Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.
    Gafni RI; Guthrie LC; Kelly MH; Brillante BA; Christie CM; Reynolds JC; Yovetich NA; James R; Collins MT
    J Bone Miner Res; 2015 Nov; 30(11):2112-8. PubMed ID: 25990370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women.
    Rapuri PB; Kinyamu HK; Gallagher JC; Haynatzka V
    J Clin Endocrinol Metab; 2002 May; 87(5):2024-32. PubMed ID: 11994336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.
    Zhang G; Qin L; Shi Y
    J Bone Miner Res; 2007 Jul; 22(7):1072-9. PubMed ID: 17419678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
    Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25-dihydroxyvitamin D (Calcitriol) for four years.
    Sairanen S; Kärkkäinen M; Tähtelä R; Laitinen K; Mäkelä P; Lamberg-Allardt C; Välimäki MJ
    Calcif Tissue Int; 2000 Aug; 67(2):122-7. PubMed ID: 10920216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial.
    Villareal DT; Binder EF; Williams DB; Schechtman KB; Yarasheski KE; Kohrt WM
    JAMA; 2001 Aug; 286(7):815-20. PubMed ID: 11497535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.